MARKET

CPRX

CPRX

Catalyst Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.130
-0.010
0.00%
Closed 19:24 08/04 EDT
OPEN
4.120
PREV CLOSE
4.130
HIGH
4.170
LOW
4.050
VOLUME
2.21M
TURNOVER
--
52 WEEK HIGH
7.67
52 WEEK LOW
2.550
MARKET CAP
427.11M
P/E (TTM)
10.25
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CPRX stock price target is 8.25 with a high estimate of 10.00 and a low estimate of 6.50.

EPS

CPRX News

More
Here's How Much Investing $1,000 In Catalyst Pharmaceuticals In 2010 Would Be Worth Today
Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way.
Benzinga · 17h ago
Immunic Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 1d ago
Catalyst Pharmaceuticals Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of Stockholders
CORAL GABLES, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chron
GlobeNewswire · 1d ago
Catalyst Pharmaceuticals to Hold Second Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 11th, 2020
CORAL GABLES, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chron
GlobeNewswire · 1d ago
TAOP, KODK among premarket losers
Seeking Alpha · 4d ago
Catalyst Pharma down 13% on adverse ruling in FDA lawsuit
Seeking Alpha · 5d ago
Earnings Preview: Catalyst Pharmaceutical (CPRX) Q2 Earnings Expected to Decline
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 6d ago
Did Hedge Funds Make The Right Call On Catalyst Pharmaceuticals, Inc. (CPRX) ?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of
Insider Monkey · 07/28 15:11

Industry

Biotechnology & Medical Research
+0.02%
Pharmaceuticals & Medical Research
-0.36%

Hot Stocks

Symbol
Price
%Change

About CPRX

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
More

Webull offers kinds of Catalyst Pharmaceuticals Inc stock information, including NASDAQ:CPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CPRX stock methods without spending real money on the virtual paper trading platform.